398 results on '"Lacouture, Mario E."'
Search Results
2. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
3. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
4. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD
5. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
6. IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
7. 1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors
8. Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
9. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
10. Dermatological Complications of Systemic Therapies for Melanoma
11. Photosensitivity and Photoreactions
12. Hair Disorders
13. Introduction to Anticancer Therapies
14. Dermatologic Toxicities
15. Cutaneous Adverse Events of Systemic Melanoma Treatments
16. Dermatological Complications of Systemic Therapies for Melanoma
17. Cutaneous Adverse Events of Systemic Melanoma Treatments
18. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients
19. Supplementary Table 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
20. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
21. Data from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
22. Table S2 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
23. Table S1 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
24. Supplementary Figure 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
25. Table S2 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
26. Data from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
27. Supplementary Figure 1 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
28. Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
29. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
30. Supplementary Figure Legends from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
31. Supplemental Table 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
32. Supplemental Figure 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
33. Supplementary Table 3 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
34. Table S3 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
35. Supplementary Table 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
36. Figure S1 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
37. Supplementary Tables S1-S10 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
38. Supplemental Table 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
39. Data from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
40. Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
41. Supplementary Figure 2 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
42. Supplementary Table 1 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
43. Supplementary Table 1 from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
44. Supplemental Table 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
45. Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
46. Data from Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
47. Figure S2 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
48. Table S3 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
49. Figure S1 from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
50. Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.